SOFIE Biosciences
SOFIE Biosciences is a US radiopharmacy network running two phase 3 trials of the FAP PET tracer [18F]FAPI-74 in pancreatic and gastro-oesophageal cancer.
First patients dosed in the FAPI-GO (gastro-oesophageal, December 2025) and pancreatic (February 2026) phase 3 trials; seven radiopharmacies cleared to manufacture [18F]FAPI-74 with 12-hour shelf-life distribution planned in 2026. FAPI chemistry originated in Heidelberg.
Pages like this
not linked directly; found by shared links- CompanyJubilant Radiopharma
Shares PET tracer manufacturing and distribution, Radiopharmacy and cyclotron networks.
- CompanyPETNET Solutions (Siemens Healthineers)
Shares PET tracer manufacturing and distribution, Radiopharmacy and cyclotron networks.
- CompanyCardinal Health Nuclear & Precision Health Solutions
Shares PET tracer manufacturing and distribution, Radiopharmacy and cyclotron networks.
- PersonFrederik Giesel
Shares Heidelberg University Hospital / NCT / DKFZ, FAPI PET, FAP.
- IdeaFAP theranostics as a pan-cancer stromal strategy
Shares FAPI PET, FAP, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.
- IdeaFAPI PET as the workup for MCED positives
Shares FAPI PET, FAP, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.
- TechnologyCAR-T against stroma: fibroblasts and myeloid cells
Shares FAPI PET, FAP, Pancreatic ductal adenocarcinoma.
- IdeaDedicated cohorts for patients with performance status 2 in first-line trials
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.